JP7439046B2 - Ｃｄ１９に結合する重鎖抗体 - Google Patents

Ｃｄ１９に結合する重鎖抗体 Download PDF

Info

Publication number
JP7439046B2
JP7439046B2 JP2021502833A JP2021502833A JP7439046B2 JP 7439046 B2 JP7439046 B2 JP 7439046B2 JP 2021502833 A JP2021502833 A JP 2021502833A JP 2021502833 A JP2021502833 A JP 2021502833A JP 7439046 B2 JP7439046 B2 JP 7439046B2
Authority
JP
Japan
Prior art keywords
heavy chain
antibody
antibodies
sequence
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530236A5 (enExample
JP2021530236A (ja
Inventor
シェリー フォース オルドレッド，
ショーテン， ウィム ヴァン
キャサリン ハリス，
ウダヤ ランガスワーミィ，
ネイサン トリンクライン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TeneoTwo Inc
Original Assignee
TeneoTwo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TeneoTwo Inc filed Critical TeneoTwo Inc
Publication of JP2021530236A publication Critical patent/JP2021530236A/ja
Publication of JP2021530236A5 publication Critical patent/JP2021530236A5/ja
Priority to JP2024020312A priority Critical patent/JP7737488B2/ja
Application granted granted Critical
Publication of JP7439046B2 publication Critical patent/JP7439046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021502833A 2018-07-20 2019-07-19 Ｃｄ１９に結合する重鎖抗体 Active JP7439046B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024020312A JP7737488B2 (ja) 2018-07-20 2024-02-14 Ｃｄ１９に結合する重鎖抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701281P 2018-07-20 2018-07-20
US62/701,281 2018-07-20
PCT/US2019/042633 WO2020018922A1 (en) 2018-07-20 2019-07-19 Heavy chain antibodies binding to cd19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020312A Division JP7737488B2 (ja) 2018-07-20 2024-02-14 Ｃｄ１９に結合する重鎖抗体

Publications (3)

Publication Number Publication Date
JP2021530236A JP2021530236A (ja) 2021-11-11
JP2021530236A5 JP2021530236A5 (enExample) 2022-07-26
JP7439046B2 true JP7439046B2 (ja) 2024-02-27

Family

ID=67515196

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502833A Active JP7439046B2 (ja) 2018-07-20 2019-07-19 Ｃｄ１９に結合する重鎖抗体
JP2024020312A Active JP7737488B2 (ja) 2018-07-20 2024-02-14 Ｃｄ１９に結合する重鎖抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024020312A Active JP7737488B2 (ja) 2018-07-20 2024-02-14 Ｃｄ１９に結合する重鎖抗体

Country Status (22)

Country Link
US (1) US12202898B2 (enExample)
EP (2) EP3823990B1 (enExample)
JP (2) JP7439046B2 (enExample)
KR (2) KR20260036383A (enExample)
CN (2) CN116769032A (enExample)
AU (2) AU2019305663B2 (enExample)
BR (1) BR112020024074A2 (enExample)
CA (1) CA3101069A1 (enExample)
DK (1) DK3823990T3 (enExample)
ES (1) ES3064933T3 (enExample)
FI (1) FI3823990T3 (enExample)
HR (1) HRP20260372T1 (enExample)
IL (2) IL326259A (enExample)
LT (1) LT3823990T (enExample)
MX (1) MX2021000708A (enExample)
PL (1) PL3823990T3 (enExample)
PT (1) PT3823990T (enExample)
RS (1) RS67881B1 (enExample)
SG (1) SG11202011597RA (enExample)
SI (1) SI3823990T1 (enExample)
SM (1) SMT202600121T1 (enExample)
WO (1) WO2020018922A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2021188599A1 (en) * 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
UA130700C2 (uk) * 2020-04-29 2026-04-22 Тенеобіо, Інк. Поліспецифічні антитіла, що містять тільки важкі ланцюги, з модифікованими константними областями важкого ланцюга
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CA3186065A1 (en) * 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
MX2023009882A (es) * 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
PE20260568A1 (es) * 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
EP4566619A1 (en) * 2023-12-08 2025-06-11 AvenCell Therapeutics Inc. Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
TW202608445A (zh) * 2024-04-19 2026-03-01 美商泰尼歐圖股份有限公司 用於治療ｂ－細胞惡性腫瘤之阿卡替尼（ａｃａｌａｂｒｕｔｉｎｉｂ）及多特異性抗體之治療組合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025038A1 (en) 2015-08-11 2017-02-16 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2018039180A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20060008548A1 (en) 2003-11-19 2006-01-12 Invista North America S.A R.L. Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2009272771B2 (en) * 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
US9914683B2 (en) 2016-05-26 2018-03-13 X Development Llc Fuel synthesis from an aqueous solution
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
WO2019006072A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
BR112020023975A2 (pt) 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025038A1 (en) 2015-08-11 2017-02-16 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2018039180A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Iranian Journal of Basic Medical Sciences，2018年05月，Vol.21, No.5，pp.455-464

Also Published As

Publication number Publication date
US12202898B2 (en) 2025-01-21
DK3823990T3 (da) 2026-03-16
IL326259A (en) 2026-03-01
RS67881B1 (sr) 2026-04-30
BR112020024074A2 (pt) 2021-02-17
PT3823990T (pt) 2026-03-20
CN112351997B (zh) 2023-05-26
AU2019305663A1 (en) 2021-03-11
SI3823990T1 (sl) 2026-05-29
WO2020018922A1 (en) 2020-01-23
SMT202600121T1 (it) 2026-05-12
FI3823990T3 (fi) 2026-03-16
JP2021530236A (ja) 2021-11-11
KR102930803B1 (ko) 2026-02-26
LT3823990T (lt) 2026-04-10
HRP20260372T1 (hr) 2026-04-24
SG11202011597RA (en) 2020-12-30
CN116769032A (zh) 2023-09-19
EP3823990A1 (en) 2021-05-26
JP2024073430A (ja) 2024-05-29
IL279010B1 (en) 2026-03-01
IL279010A (en) 2021-01-31
KR20260036383A (ko) 2026-03-16
PL3823990T3 (pl) 2026-04-20
EP4714502A2 (en) 2026-03-25
JP7737488B2 (ja) 2025-09-10
US20210332133A1 (en) 2021-10-28
AU2019305663B2 (en) 2026-04-02
CA3101069A1 (en) 2020-01-23
KR20210032311A (ko) 2021-03-24
AU2026205247A1 (en) 2026-07-23
EP3823990B1 (en) 2025-12-17
MX2021000708A (es) 2021-03-25
CN112351997A (zh) 2021-02-09
ES3064933T3 (en) 2026-04-30
IL279010B2 (en) 2026-07-01

Similar Documents

Publication Publication Date Title
JP7737488B2 (ja) Ｃｄ１９に結合する重鎖抗体
US12180298B2 (en) Heavy chain antibodies binding to PSMA
JP7665538B2 (ja) Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
US20240117063A1 (en) Anti-cd20 antibodies and car-t structures
JP2024507540A (ja) 抗ｐｓｍａ抗体及びｃａｒ－ｔ構造
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
CA3211142A1 (en) Anti-muc1-c antibodies and car-t structures
RU2824170C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd19
HK40100966A (en) Heavy chain antibodies binding to cd19
EA049498B1 (ru) Антитела к cd20 и car-t-клеточные структуры
HK40044275A (en) Heavy chain antibodies binding to cd19
HK40044275B (en) Heavy chain antibodies binding to cd19
EA048216B1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7439046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150